Exelixis, Inc. (EXEL) - Financial and Strategic SWOT Analysis Review

Document Sample
Exelixis, Inc. (EXEL) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					           Exelixis, Inc. (EXEL) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDPH36523FSA                                                                                          Publication Date: MAR 2013

          210 East Grand Avenue, P.O. Box 511                Phone              +1 650 8377000                  Revenue          47.4 (million USD)
          So. San Francisco, CA                              Fax                +1 650 8378300                  Net Profit       75.70 (million USD)
          94080                                              Website            www.exelixis.com                Employees        200
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           EXEL [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Exelixis, Inc. (Exelixis) is a biotechnology company. It is focused on the development of pharmaceutical products for treatment of
       cancer and other life threatening diseases. The company’s lead drug candidate Cabozantinib (XL184), is administered for the
       treatment of medullary thyroid cancer (MTC), metastatic castration-resistant prostate cancer, ovarian cancer, breast cancer,
       gastric/ge junctional cancer, hepatocellular carcinoma, melanoma, castration-resistant prostate cancer, non-small cell lung
       cancer, ovarian cancer, pancreatic cancer, small cell lung cancer differentiated thyroid cancer and renal cell carcinoma.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Exelixis, Inc., SWOT Analysis
         Michael Morrissey, Ph.D.            Chief Executive Officer                  Strengths                              Weaknesses
         Stelios        Papadopoulos, Chairman
                                                                                      Strategic Collaborations               Lack of Manufacturing
         Ph.D.
                                                                                                                             Capabilities
         George A. Scangos, Ph.D.            Director                                 Orphan Drug Designation –
                                                                                      Cabozantinib                           Lack of Marketed Products
         Charles Cohen, Ph.D.                Director
         Carl B. Feldbaum                    Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Focused R&D Activities                 Tightening of FDA’s Regulatory
       Share Data                                                                                                            Oversight
                                                                                      Changing Demographics
         Exelixis, Inc.
                                                                                                                             Uncertain R&D Outcomes
        Share Price (USD) as on 08-Mar-                                  4.80
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (USD)                                                        0.58        GlobalData
        Market Cap (million USD)                                         881
        Enterprise Value (million USD)                                   908
        Shares Outstanding (million)                                     184
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Feb 21, 2013         Exelixis Reports Revenue Of $7.8m In Q4
                                                                                                           2012
                                                                                      Nov 07, 2012         Exelixis Reports Revenue Of $13.3m In Q3
                                                                                                           2012
                                                                                      Aug 02, 2012         Exelixis Reports Total Revenue Of $7.8m For
                                                                                                           Q2 2012
                                                                                      May 03, 2012         Exelixis Reports Revenue Of $18.5m In Q1
                                                                                                           2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Exelixis, Inc. (EXEL) - Financial and Strategic SWOT Analysis                                                                  Reference Code: GDPH36523FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Exelixis, Inc. - Key Facts .................................................................................................................................................................... 5
       Exelixis, Inc. - Key Employees ........................................................................................................................................................... 6
       Exelixis, Inc. - Key Employee Biographies ......................................................................................................................................... 7
       Exelixis, Inc. - Major Products and Services....................................................................................................................................... 9
       Exelixis, Inc. - Pharmaceutical Pipeline Products Data .................................................................................................................... 10
          Exelixis, Inc., Pipeline Products by Therapy Area......................................................................................................................... 10
          Exelixis, Inc., Pipeline Products by Development Phase .............................................................................................................. 11
       Exelixis, Inc. - History ....................................................................................................................................................................... 14
       Exelixis, Inc. - Company Statement.................................................................................................................................................. 17
       Exelixis, Inc. - Locations And Subsidiaries ....................................................................................................................................... 19
          Head Office ................................................................................................................................................................................... 19
          Other Locations & Subsidiaries ..................................................................................................................................................... 19
       Section 2 – Company Analysis ......................................................................................................................................................... 20
       Exelixis, Inc. - Business Description ................................................................................................................................................. 20
       Exelixis, Inc. - SWOT Analysis ......................................................................................................................................................... 21
          SWOT Analysis - Overview........................................................................................................................................................... 21
          Exelixis, Inc. - Strengths ............................................................................................................................................................... 21
             Strength - Strategic Collaborations ........................................................................................................................................... 21
             Strength - Orphan Drug Designation – Cabozantinib ............................................................................................................... 21
             Strength - Sound Financial Performance .................................................................................................................................. 21
          Exelixis, Inc. - Weaknesses .......................................................................................................................................................... 22
             Weakness - Lack of Manufacturing Capabilities ........................................................................................................................ 22
             Weakness - Lack of Marketed Products .................................................................................................................................... 22
          Exelixis, Inc. - Opportunities ......................................................................................................................................................... 22
             Opportunity - Focused R&D Activities ....................................................................................................................................... 22
             Opportunity - Changing Demographics ..................................................................................................................................... 22
             Opportunity - Focus on Oncology Market .................................................................................................................................. 23
          Exelixis, Inc. - Threats................................................................................................................................................................... 23
             Threat - Tightening of FDA’s Regulatory Oversight ................................................................................................................... 23
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 23
             Threat - Increased Pricing Control............................................................................................................................................. 23
       Exelixis, Inc. - Key Competitors ........................................................................................................................................................ 24
       Section 3 – Company Financial Ratios ............................................................................................................................................. 25
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 25
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 25
       Performance Chart ........................................................................................................................................................................... 27
       Financial Performance...................................................................................................................................................................... 27
       Financial Ratios - Interim Ratios....................................................................................................................................................... 28
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 29
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 30
          Exelixis, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ........................................................................ 30


Exelixis, Inc. (EXEL) - Financial and Strategic SWOT Analysis                                                                                                  Reference Code: GDPH36523FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Exelixis, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013........................................................................ 31
       Exelixis, Inc., Recent Deals Summary .............................................................................................................................................. 32
       Section 5 – Company’s Recent Developments ................................................................................................................................ 33
          Exelixis, Inc., Recent Developments ............................................................................................................................................. 33
             Feb 21, 2013: Exelixis Reports Revenue Of $7.8m In Q4 2012 ................................................................................................ 33
             Nov 07, 2012: Exelixis Reports Revenue Of $13.3m In Q3 2012.............................................................................................. 34
             Aug 02, 2012: Exelixis Reports Total Revenue Of $7.8m For Q2 2012 .................................................................................... 35
             May 03, 2012: Exelixis Reports Revenue Of $18.5m In Q1 2012 ............................................................................................. 36
             Feb 08, 2012: Exelixis Reports Revenue Of $93.3m In Q4 2011 ..........................................................................................
				
DOCUMENT INFO
Description: Exelixis, Inc. (Exelixis) is a biotechnology company. It is focused on the development of pharmaceutical products for treatment of cancer and other life threatening diseases. The company’s lead drug candidate Cabozantinib (XL184), is administered for the treatment of medullary thyroid cancer (MTC), metastatic castration-resistant prostate cancer, ovarian cancer, breast cancer, gastric/ge junctional cancer, hepatocellular carcinoma, melanoma, castration-resistant prostate cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, small cell lung cancer differentiated thyroid cancer and renal cell carcinoma.
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.